Life Science News

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: ATURF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") is pleased to announce that it has successfully demonstrated colorimetric detection of SARS-CoV-2, the virus that causes COVID-19 (the "Virus") utilizing the Company's patent pending Accelerated Molecular Imprinted Polymers ("AMIPs™") technology.

Colorimetric detection is a method of identifying the presence of a target substance within a test sample by means of a color reagent. When successfully applied, the activation of the reagent indicates the presence of the target substance.

The demonstration, performed by way of a simulated synthetic enzyme-linked immunosorbent assay ("ELISA") test, is represented by the following microscopic images:

Fig 1: Colorimetric Response of AMIPsTM to SARS-CoV-2 Virus

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5010/80276_6c978d37b4f5ea5c_001full_300.jpg         Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5010/80276_6c978d37b4f5ea5c_002full_300.jpg

The image on the left shows the AMIPs™ polymer having been exposed to SARS-CoV-2, with the fluorescent highlights indicating the presence of the Virus. The image on the right shows the AMIPs™ polymer having been exposed to a non-infected sample. (Images produced using Olympus spinning disk Confocal microscope at ONLY 20x magnification).

The Company intends to build on this initial validation toward the development of a colorimetric sensor for a potentially wide range of rapid Virus detection devices using AMIPs™. The spectrum of prospective products includes SIXW's SmartMask™ (see SIXW Press Release dated May 15, 2020), in addition to, airborne sensors, breathalyzers, synthetic ELISA-like tests, cartridge/lateral flow tests, and others.

"Colorimetric detection is an important development for AMIPs™ technology," said Dr. Jon Gluckman, President and CEO of Sixth Wave. "As previously disclosed, the AMIPs polymer captures the COVID-19 virus, as intended, and is now supported by three independent analytical methods. Two primary objectives of any rapid diagnostic tool are definitive results and ease of interpretation. Colorimetric Sensors can deliver on both fronts and this is a material step in that direction."

"As previously disclosed, AMIPs™ are designed to be resistant to loss in efficacy due to virus mutation and emergence of variants which may change the specific antibody/antigen reaction but have yet to create gross changes to the size and shape of the Virus. AMIPs™ also has the potential to identify multiple types of viruses (coronavirus, influenza virus, rhinovirus etc.) in a single platform," said Garrett Kraft, Sixth Wave's Lead AMIPs™ researcher. "The confirmation of colorimetric detection from this test opens the possibility of deploying a palette of colors to identify multiple viruses in a single pass such as influenza AND COVID-19 with different colors for each. This potential for independent color coding is perhaps the most promising aspect of AMIPs™ as a versatile diagnostic tool. Ideally, our end AMIPs™ product will be a 'Swiss Army Knife' of sorts, performing multiple diagnostic tests in a single application."

The Company is not making any express or implied claims that its product has the ability to eliminate, cure, contain, or detect, at a commercial level, COVID-19 (or SARS-2 coronavirus) at this time.

Details on Initial Colorimetric Detection Test Work

The test performed was designed to simulate an ELISA test but using AMIPs™. ELISA tests are a go-to detection technology employed extensively in the health services arena. In its most basic form, ELISA starts by isolating a target pathogen such as SARS-CoV-2(the "Antigen"). The Antigen is immobilized on a solid surface known as a microplate. An antibody targeted for the pathogen (the "Antibody"), will have an associated enzyme (the "Reporter Enzyme"). When the Antibody binds to the immobilized Antigen the Reporter Enzyme is chemically bound to the virus. The sample is rinsed to remove unbound Reporter Enzyme, only leaving the Reporter Enzymes that are bound to the virus. An indicator solution is incubated with the sample and any Reporter Enzymes in the sample will catalyze a chemical reaction, thus inducing a color change. From the color change, the researcher can infer that binding between the Antigen and Antibody has occurred, and that the target pathogen (the Virus) is present. The foregoing process produces the colorimetric response that represents detection of a virus.

Using the foregoing ELISA methodology as a starting point, Sixth Wave researchers modified the technique to accommodate the unique features of AMIPs™ molecular imprinting technology. As with all immunoassay tests, ELISA tests require the use of an Antibody-Antigen binding for detection. AMIPs™ replaces the Antibody with a molecular imprint of the whole Virus, and replaces the Antibody with the AMIPs™ imprinted polymer. A chemically engineered binding mechanism built into the polymer, provides a force of attraction between the Virus and the AMIPs™ eliminating any need of biological material including Antibodies. The Reporter Enzymes in classic ELISA tests help amplify the color response making detection easier and, while it was not needed in this test, may be useful in certain AMIPs™ products. The value of AMIPs™ in this regard is multifold:

  • Simplicity & Flexibility - AMIPs™ test does not require the use of Antibodies, which are biological materials subject to supply chain complexity (must be grown in host animals subsequently sacrificed, stored/transported under refrigeration/freezing), degradation from environmental factors (heat, sun, etc.) which limit how they can be deployed, and as of yet have not been easily configured to detect multiple viruses in a single test. In an ELISA type configuration AMIPs™ can provide the same performance and form factor clinical laboratory workers are accustom to while providing a robust, reliable, and lower cost product.
  • Robust Detection Capability - AMIPs™ should be more robust in its ability to detect variants of COVID-19. This is because the mechanism used to capture and immobilize the Virus is not keyed to a specific Antigen-Antibody relationship. The Antigen-Antibody relationship is based on antibody interactions with a small section of a viral protein. This interaction is highly specific but constantly challenged with an ever-changing set of variables due to natural mutation, with significant changes in the Antigen (virus) making it resistant or "invisible" to existing Antibodies.
  • Variants - As already well documented for many viruses (i.e COVID-19 and influenza) several of the variants of COVID-19 are more transmittable and more deadly (including the United Kingdom, South African, and Brazilian variants) due to such mutation. Immunoassay tests as a class which rely on Antibodies for immobilization and detection of the Virus are ultimately subject to the same inherent potential to miss both known and emergent variants in the same way the human body's immunity can be bypassed and as such may be much more susceptible to false negative results than the more wholistic capture and detection methods implemented in AMIPs™.
  • Additional Validation - The AMIPs test provides additional validation that the AMIPs™ polymer works. The latter being in addition to the QCM/QCM-D and AFM confirmations previously announced.

The research results obtained directly compared the prototype AMIPs™ polymer against infected and non-infected cell cultures to ensure detection was based on the presence of the virus and not binding of any other components of the cellular milieu or non-specific interactions between the polymer and the fluorescent dye. Detection was observed using an Olympus spinning disk Confocal microscope. In lay terms, two AMIP™ sensors were used in the experiment. One sensor was exposed to an infected cell culture solution and the other sensor was exposed to a non-infected cell culture solution. Both sensors were then washed to remove unbound material. The AMIPs™ were then exposed to the off-the-shelf florescent dye in accordance with the manufacturer's standard protocols. The dye has chemical functionalities that will react non-specifically with most proteins. The dye solution was then washed off and the sensors were imaged under the microscope at 20x magnification. The results were overwhelmingly clear - AMIPs™ showed detection. No florescent response was observed from the sensor exposed to non-infected cell culture solution. The results demonstrate that the AMIPs polymer selectively binds the SARS-CoV-2 virus and that there are no non-specific interactions between the AMIP polymer and common cellular components or interferants.

Completion of Briefing to Nova Scotia COVID-19 Response Council

The Company is also pleased to report that it has successfully completed its final briefing to the Nova Scotia COVID-19 Response Council. This was well received and represents the final deliverable under the awarded Contribution Agreement previously announced on October 27, 2020 (the "Council" and the "Contribution Agreement ", respectively).

For more information on the AMIPs™ and associated molecular imprinting technology, please visit: https://www.amips.com

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our web site at: www.sixthwave.com

ON BEHALF OF THE BOARD OF DIRECTORS

"Jonathan Gluckman"
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed "forward-looking statements" including statements regarding the planned use of proceeds and performance of the AMIPs™ technologies. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the AMIPs™ technology are subject to the risk that the AMIPs™ technology may not prove to be successful in detecting virus targets effectively or at all, the uncertainty of medical product development, the uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company has not yet completed the development of a prototype for the product that is subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80276

News Provided by Newsfile via QuoteMedia

two open palms hold a sphere representing the earth with water in the background

Sustainable Packaging: Increasing Demand for Natural Solutions

We only have one planet — and until recently we've done a poor job taking care of it.

The packaging industry is one of the sectors in which this is most evident. With a projected market size of US$1.13 trillion by 2030, it also represents one of the most significant sources of pollution in the world. Globally, we produce roughly 380 million tons of plastic per year. Single-use items such as grocery bags, bottles and packaging represent around 50 percent of that number.

To put this into context, the plastic waste produced by soft drink companies could cover 83 football fields a day, and the pollution footprint of packaging is at least as bad.

Keep reading...Show less
Billy Goat Brands CEO Tony Harris

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainability

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainabilityyoutu.be

Keep reading...Show less
Albert Labs

Albert Labs Granted Health Canada Licence

Albert Labs has been issued a Health Canada License enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substances

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines for mental health treatments, is pleased to report it has been granted a Health Canada License dated 05-05-2022 for its research and production facility in Burnaby, Canada . This approval permits the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances within the confines of the regulations governing controlled substances.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022 .

Universal Ibogaine Co Founder Dr. Alberto Sola to present at From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine (CNW Group/Universal Ibogaine Inc.)

The Research to Reality event is presented by the Mental Health Commission of Canada , the Center for Addiction and Mental Health ("CAMH") and the Canadian Center on Substance Abuse and Addiction.

The event will be attended by researchers, clinicians' policy makers including representatives from Health Canada the FDA and the Mexico Ministry of Health ("COFEPRIS").

Dr. Sola, is a co-founder of Universal Ibogaine and a member of the Board of Directors, and he is the founder of the Clear Sky Recovery ibogaine clinic operating in Cancun , Mexico.  Alberto is a global leader in ibogaine detox treatments. He will present his latest findings in a panel titled " Ibogaine Hydrochloride and Acute Opioid Detox ., which will take place on Saturday May 28 at 4:15 PM EST "

UI CEO Nick Karos noted: "The importance of this event cannot be overstated.  This is the first event of its kind to bring together academic researchers, real world technicians and government policy makers. We believe this event will be an important catalyst for the industry and a significant milestone for our company.  This event will create awareness at the highest levels of the incredible potential of ibogaine."

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.
Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Related Links
https://universalibogaine.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-ibogaine-co-founder-dr-alberto-sola-to-present-at-upcoming-research-to-reality-conference-301547153.html

SOURCE Universal Ibogaine Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2022/13/c5432.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Albert Labs

Albert Labs' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies

World-renowned scientists from the University of CESPU Health Sciences Department, Portugal are working in partnership with Albert Labs' expert team to conduct safety and toxicology studies, in preparation for KRN-101's use in Real World Evidence studies.

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical quality medicines, based on the mycelia of Psilocybe, today released further details of their ongoing preclinical studies. These are currently being conducted at the University of Health Sciences, CESPU, Portugal . The partnership established between Albert Labs and CESPU, provides Albert Labs with preclinical drug assessment capabilities, both in vivo and in vitro. The current work programme provides essential data on Albert Labs' mycelium-based pharmaceutical products in support of clinical trials due to start later this year. The clinical programme will investigate the potential to treat cancer-related distress, an indication thought to affect approximately 15 million patients worldwide.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
NeonMind Biosciences

NeonMind Biosciences: Using Psychedelics as Treatment for Mental Health Disorders and Weight Management

NeonMind Biosciences (CSE:NEON,OTCQB:NMDBF,FRA:6UF) has launched its campaign on the Investing News Network's Life Science and Psychedelics channels.

NeonMind Biosciences (CSE:NEON,OTCQB:NMDBF,FRA:6UF) is a drug development and healthcare company pioneering innovative ways to bring transformational mental health treatments to market with a focus on psychedelics. The company aims to improve access to psychedelic treatments with two strategies:

  1. Establishing specialized mental health clinics that provide currently available treatments such as ketamine and esketamine and to provide other psychedelic treatments when approved.
  2. Focusing on drug development of novel psychedelic treatments focusing on their proprietary drug candidates to treat behavioral deficits in patients with weight management issues and obesity.

Medical mushrooms for psychedelic treatmentMedical mushrooms for psychedelic treatmentinvestingnews.com

Keep reading...Show less

Latest Press Releases

Related News

×